Login to Your Account

InterMune Halts All Cancer Research Into Actimmune

By Aaron Lorenzo

Monday, February 6, 2006
InterMune Inc. stopped a Phase III trial of Actimmune (interferon gamma-1b) in ovarian cancer due to ineffectiveness and will not plan any further oncology studies of the product going forward, as it falls outside the company's core focus. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription